FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. | 20549 |
|-------------|------|-------|
|-------------|------|-------|

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | |
|----------------------|-----------|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | |
| Estimated average to | ourden | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* FRIESON RON | | | | <u>A</u> | 2. Issuer Name and Ticker or Trading Symbol Akebia Therapeutics, Inc. [AKBA] | | | | | | | | | k all application | r | | 10% Ov | ner | |
|---|--|------------|-------------|--------------|--|---|---------|--|-------------------|---|--------------------|--------------------------------------|---|---|-------------------------------------|--|--|--------------------|------------|
| (Last) | (F | irst) | (Middle) | | | 3. Date of Earliest Transaction (Month/Day/Year) 06/06/2024 | | | | | | | | | officer (below) | (give title | | Other (s below) | pecify |
| C/O AKEBIA THERAPEUTICS, INC. 245 FIRST STREET | | | | 4. I | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | Line) | 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person | | | | | | |
| (Street) | IDGE M | Ā | 02142 | | _ | Form filed by More than One Report Person | | | | | | | | | | ting | | | |
| (City) | (City) (State) (Zip) | | | | | Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | | | |
| | | Tal | ole I - Nor | n-Deri | vativ | e Se | curitie | s Ac | quired, | Dis | posed o | f, or Be | nefi | icially | Owned | | | | |
| 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date) | | | | | Execution | | | Code (| | | | 4 and 5) Securition Benefici Owned I | | es Form ially (D) (Following (I) (I | | : Direct Indirect str. 4) | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | | | Code | v | Amount | (A) (D) | or F | Price | Reported Transact (Instr. 3 a | tion(s) | | | (Instr. 4) |
| Common Stock 06/06 | | | | | 6/202 | 6/2024 | | | | | 30,000 |) ⁽¹⁾ A | | \$0.00 | 73,700 | | | D | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | Derivative Conversion Date Execution Date courity or Exercise (Month/Day/Year) if any | | ate, | Code (Instr. | | n of i | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | curity | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4) | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | | |
| | | | | | Code | v | (A) | (D) | Date Exercisab | | Expiration Date | Title | or Nu of | ımber | | | | | |
| Stock Option (Right to buy) | \$1.07 | 06/06/2024 | | | A | | 45,000 | | 06/06/2023 | 5(2) | 06/06/2034 | Commor Stock | 45 | 5,000 | \$0.00 | 45,000 |) | D | |

Explanation of Responses:

- 1. The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Third Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer.
- 2. The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer.

Remarks:

/s/ Carolyn Rucci, attorney-infact for Ronald E. Frieson

06/10/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.